Avior Wealth Management LLC Has $482,000 Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Avior Wealth Management LLC cut its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 9.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,097 shares of the biotechnology company’s stock after selling 1,670 shares during the quarter. Avior Wealth Management LLC’s holdings in Rocket Pharmaceuticals were worth $482,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. VELA Investment Management LLC lifted its stake in Rocket Pharmaceuticals by 29.2% in the fourth quarter. VELA Investment Management LLC now owns 20,773 shares of the biotechnology company’s stock valued at $623,000 after buying an additional 4,694 shares during the period. Vontobel Holding Ltd. bought a new position in Rocket Pharmaceuticals during the fourth quarter worth $1,305,000. WCM Investment Management LLC grew its holdings in Rocket Pharmaceuticals by 2.5% in the fourth quarter. WCM Investment Management LLC now owns 296,013 shares of the biotechnology company’s stock worth $9,147,000 after purchasing an additional 7,212 shares during the period. Arizona State Retirement System increased its stake in Rocket Pharmaceuticals by 17.6% in the fourth quarter. Arizona State Retirement System now owns 18,864 shares of the biotechnology company’s stock valued at $565,000 after purchasing an additional 2,828 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Rocket Pharmaceuticals by 404.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,424 shares of the biotechnology company’s stock valued at $312,000 after purchasing an additional 8,356 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals Stock Down 0.8 %

Shares of RCKT stock opened at $23.48 on Friday. Rocket Pharmaceuticals, Inc. has a 12 month low of $14.89 and a 12 month high of $32.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.80 and a current ratio of 7.80. The firm’s 50 day moving average is $27.33 and its 200 day moving average is $25.26.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.14. During the same quarter in the previous year, the firm posted ($0.92) EPS. As a group, research analysts expect that Rocket Pharmaceuticals, Inc. will post -2.94 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director David P. Southwell sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $24.05, for a total value of $240,500.00. Following the completion of the sale, the director now directly owns 114,784 shares in the company, valued at approximately $2,760,555.20. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Rocket Pharmaceuticals news, Director David P. Southwell sold 10,000 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $24.05, for a total value of $240,500.00. Following the completion of the sale, the director now directly owns 114,784 shares of the company’s stock, valued at $2,760,555.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kinnari Patel sold 7,132 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $29.84, for a total value of $212,818.88. Following the transaction, the insider now directly owns 238,346 shares in the company, valued at $7,112,244.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 414,740 shares of company stock worth $11,474,727. Corporate insiders own 31.10% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on RCKT. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, February 27th. StockNews.com upgraded shares of Rocket Pharmaceuticals to a “sell” rating in a report on Friday, February 9th. JPMorgan Chase & Co. decreased their price objective on Rocket Pharmaceuticals from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Tuesday, February 27th. The Goldman Sachs Group started coverage on Rocket Pharmaceuticals in a research report on Tuesday, April 2nd. They set a “neutral” rating and a $39.00 target price on the stock. Finally, UBS Group lowered their price target on Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $52.13.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.